Somatropin pegylated - GeneScience Pharmaceuticals

Drug Profile

Somatropin pegylated - GeneScience Pharmaceuticals

Alternative Names: GenSci-004; PEG-somatropin

Latest Information Update: 09 Mar 2015

Price : $50

At a glance

  • Originator GeneScience Pharmaceuticals
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Somatotropin deficiency
  • Phase II Short stature

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Oct 2014 Phase-II clinical trials in Short stature (In children) in China (SC)
  • 30 Nov 2010 GeneScience completes a phase I trial in Somatotropin deficiency in China (NCT01613573)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top